Skip to main content

Table 3 Baseline characteristics prior to PRB initiation

From: Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study

Ā 

Group 1 (nā€‰=ā€‰5)

Group 2 (nā€‰=ā€‰10)

Median age, years (range)

37 (34ā€“45)

36 (27ā€“47)

Sex, n (%)

ā€ƒMale

4 (80)

1 (10)

ā€ƒFemale

1 (20)

9 (90)

Baseline OAT, n (%)

ā€ƒMethadone (ā‰¤ā€‰30Ā mg)a

1 (20)

1 (10)

ā€ƒOral buprenorphine lyophilisate

4 (80)

0 (0)

ā€ƒNone (out of treatment)

-

9 (90)

UDS, n (%)

ā€ƒBuprenorphine

4 (80)

2 (20)

ā€ƒMethadone

1 (20)

4 (40)

ā€ƒCocaine

0 (0)

9 (90)

ā€ƒMorphine

0 (0)

10 (100)

ā€ƒBenzodiazapine

0 (0)

6 (60)

ā€ƒAmphetamine

0 (0)

2 (20)

CGI-S score, mean (Ā±ā€‰SD)

2.6 (Ā±ā€‰0.9)

6.4 (Ā±ā€‰1.0)

SSQ score, mean (Ā±ā€‰SD)

21.8 (Ā±ā€‰1.9)

5.6 (Ā±ā€‰4.9)

CORE-10 score, mean (Ā±ā€‰SD)

5.2 (Ā±ā€‰3.3)

28.9 (Ā±ā€‰4.2)

  1. aParticipants who were stable onā€‰>ā€‰30Ā mg methadone were excluded due to the complexity and time needed to switch from high-dose methadone to PRB